Dantrolene
Dantrium, Dantrolene, Revonto, Ryanodex (dantrolene) is a small molecule pharmaceutical. Dantrolene was first approved as Dantrium on 1982-01-01. It is used to treat cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, and muscle spasticity amongst others in the USA. The pharmaceutical is active against ryanodine receptor 1. In addition, it is known to target ryanodine receptor 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Dantrium, Dantrolene, Revonto, Ryanodex (discontinued: Dantrolene)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dantrium | New Drug Application | 2024-06-24 |
| dantrolene | ANDA | 2022-02-09 |
| dantrolene sodium | ANDA | 2024-10-29 |
| revonto | ANDA | 2024-05-14 |
| ryanodex | New Drug Application | 2024-10-30 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dantrolene Sodium, Ryanodex, Eagle Pharms | |||
| 7758890 | 2025-06-30 | DP | |
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 2 | 3 | 1 | — | — | 3 |
| Heat stroke | D018883 | EFO_1001340 | T67.01 | — | 1 | 1 | — | — | 2 |
| Sunstroke | D013474 | — | T67.01 | — | 1 | 1 | — | — | 2 |
| Ventricular tachycardia | D017180 | — | I47.2 | — | 1 | 1 | — | — | 1 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | — | 1 | 1 | — | — | 1 |
| Heat stress disorders | D018882 | — | T67.2 | — | — | 1 | — | — | 1 |
| Fever | D005334 | HP_0001945 | R50.9 | — | 1 | 1 | — | — | 1 |
| Hyperthermia | D000084462 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 2 | 2 | — | — | — | 2 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | 2 | 2 | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | 1 | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | 1 | — | — | — | 1 |
| Ataxia | D001259 | — | R27.0 | 1 | 1 | — | — | — | 1 |
| Atrophy | D001284 | — | — | 1 | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | 1 | — | — | — | 1 |
| Wolfram syndrome | D014929 | Orphanet_3463 | E13.8 | 1 | 1 | — | — | — | 1 |
| Optic atrophy | D009896 | HP_0000648 | H47.2 | 1 | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dantrolene |
| INN | dantrolene |
| Description | Dantrolene is the hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia. It has a role as a muscle relaxant, a ryanodine receptor antagonist and a neuroprotective agent. It is an imidazolidine-2,4-dione and a hydrazone. It is a conjugate acid of a dantrolene(1-). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1 |
Identifiers
| PDB | — |
| CAS-ID | 7261-97-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201288 |
| ChEBI ID | — |
| PubChem CID | 2952 |
| DrugBank | DB01219 |
| UNII ID | F64QU97QCR (ChemIDplus, GSRS) |
Target
Agency Approved
RYR1
RYR1
Organism
Homo sapiens
Gene name
RYR1
Gene synonyms
RYDR
NCBI Gene ID
Protein name
ryanodine receptor 1
Protein synonyms
central core disease of muscle, protein phosphatase 1, regulatory subunit 137, ryanodine receptor 1 (skeletal), sarcoplasmic reticulum calcium release channel, Skeletal muscle calcium release channel, Skeletal muscle ryanodine receptor, Skeletal muscle-type ryanodine receptor, Type 1 ryanodine receptor, type 1-like ryanodine receptor
Uniprot ID
Mouse ortholog
Ryr1 (20190)
ryanodine receptor 1 (Q99JF9)
Alternate
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Ryanodex – Eagle Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dantrolene
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,561 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dantrolene sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
379 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use